Advertisement
Advertisement
RANI
Rani Therapeutics Holdings, Inc. Class A Common Stock
0.75
USDSponsored
-0.02
-2.35%
Sep 24, 15:55 UTC -4
Closed
Pre-Market
0.76
+0.01
+1.07%
RANI Earnings Reports
Positive Surprise Ratio
RANI beat 17 of 21 last estimates.
81%
Next Report
Date of Next Report
Nov 06, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.31M
/-$0.04
Implied change from Q2 26 (Revenue/ EPS)
-23.59%
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-66.67%
Rani Therapeutics Holdings, Inc. Class A Common Stock earnings per share and revenue
On Aug 13, 2026, RANI reported earnings of -0.04 USD per share (EPS) for Q2 26, beating the estimate of -0.05 USD, resulting in a 21.57% surprise. Revenue reached 1.71 million, compared to an expected 943.50 thousand, with a 81.03% difference. The market reacted with a +1.40% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.04 USD, with revenue projected to reach 1.31 million USD, implying an increase of 0.00% EPS, and decrease of -23.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Rani Therapeutics Holdings, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Rani Therapeutics Holdings, Inc. Class A Common Stock reported EPS of -$0.04, beating estimates by 21.57%, and revenue of $1.71M, 81.03% above expectations.
How did the market react to Rani Therapeutics Holdings, Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved up 1.4%, changed from $0.78 before the earnings release to $0.79 the day after.
When is Rani Therapeutics Holdings, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 06, 2026.
What are the forecasts for Rani Therapeutics Holdings, Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Rani Therapeutics Holdings, Inc. Class A Common Stock is expected to report EPS of -$0.04 and revenue of $1.31M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.